Abstract
This study aims to analyze dose distribution and treatment time of endobronchial brachytherapy (EBBT) by changing the position step size of the dwell position. A solid water phantom and an intraluminal catheter were used in the treatment plan. The treatment plans were generated for 3, 5, 7, and 10 cm treatment lengths, respectively. For each treatment length, the source position step sizes were set as 2.5, 5, and 10 mm. Three reference points were set 1 cm away from the central axis of the catheter, along the axis, for uniform dose distribution. Volumetric dose distribution was calculated to evaluate the dosimetric effect. The total radiation delivery time and total dwell time were estimated for treatment efficiency, which were increased with position step sizes. At half-life time, the differences between the position step sizes in the total radiation delivery time were 18.1, 15.4, 18.0, and 24.0 s for 3, 5, 7, and 10 cm treatment lengths, respectively. The dose distributions were more homogenous by increasing the position step sizes. The dose difference of the reference point was less than 10%. In brachytherapy, this difference can be negligible. For EBBT, the treatment time is the key factor while considering the patient status. To reduce the total treatment time, EBBT can be performed with 2.5 mm position step size.
REFERENCES
1. Donovan E, Timotin E, Farrell T, Donde B, Puksa S, Sur R. Endobronchial brachytherapy for metastasis from extrapulmonary malignancies as an effective treatment for palliation of symptoms. Brachytherapy. 2017; 16:630–8.
2. Nag S, Abitbol AA, Anderson LL, Blasko JC, Flores A, Harrison LB, et al. Consensus guidelines for high dose rate remote brachytherapy in cervical, endometrial, and endobronchial tumors. Int J Radiat Oncol Biol Phys. 1993; 27:1241–4.
3. Bedwinek J, Petty A, Bruton C, Sofield J, Lee L. The use of high dose rate endobronchial brachytherapy to palliate symptomatic endobronchial recurrence of previously irradiated bronchogenic carcinoma. Int J Radiat Oncol Biol Phys. 1992; 22:23–30.
4. Kelly JF, Delclos ME, Morice RC, Huaringa A, Allen PK, Komaki R. High-dose-rate endobronchial brachytherapy effectively palliates symptoms due to airway tumors: the 10-year MD Anderson cancer center experience. Int J Radiat Oncol Biol Phys. 2000; 48:697–702.
5. Perol M, Caliandro R, Pommier P, Malet C, Montbarbon X, Carrie C, et al. Curative irradiation of limited endobronchial carcinomas with high-dose rate brachytherapy: results of a pilot study. Chest. 1997; 111:1417–23.
6. Taulelle M, Chauvet B, Vincent P, Felix-Faure C, Buciarelli B, Garcia R, et al. High dose rate endobronchial brachy–therapy: results and complications in 189 patients. Eur Respir J. 1998; 11:162–8.
7. Mendiondo OA, Dillon M, Beach LJ. Endobronchial brac–hytherapy in the treatment of recurrent bronchogenic carcinoma. Int J Radiat Oncol Biol Phys. 1983; 9:579–82.
8. Huber RM, Fischer R, Haŭtmann H, Pöllinger R, Wendt T, Müller-Wening D, et al. Palliative endobronchial brachytherapy for central lung tumors: a prospective, randomized comparison of two fractionation schedules. Chest. 1995; 107:463–70.
9. Hennequin C, Tredaniel J, Chevret S, Durdux C, Dray M, Manoux D, et al. Predictive factors for late toxicity after endobronchial brachytherapy: a multivariate analysis. Int J Radiat Oncol Biol Phys. 1998; 42:21–7.
10. Langendijk H, de Jong J, Tjwa M, Muller M, ten Velde G, Aaronson N, et al. External irradiation versus external irradiation plus endobronchial brachytherapy in inoperable non-small cell lung cancer: a prospective randomized study. Radiother Oncol. 2001; 58:257–68.
11. Murakami N, Kobayashi K, Nakamura S, Wakita A, Okamoto H, Tsuchida K, et al. A total EQD2 greater than 85 Gy for trachea and main bronchus D2cc being associated with severe late complications after definitive endobronchial brachytherapy. Journal of Contemporary Brachytherapy. 2016; 8:164.
12. Moon SY, Jeong E, Lim YK, Chung WK, Huh HD, Kim DW, et al. Feasibility Study of Source Position Verification in HDR Brachytherapy Using Scintillating Fiber. Prog Med Phys. 2016; 27:213–9.
13. Delclos ME, Komaki R, Morice RC, Allen PK, Davis M, Garden A. Endobronchial brachytherapy with high-dose-rate remote afterloading for recurrent endobronchial lesions. Radiology. 1996; 201:279–82.
14. Gustafson G, Vicini F, Freedman L, Johnston E, Edmundson G, Sherman S, et al. High dose rate endobronchial bra–chytherapy in the management of primary and recurrent bronchogenic malignancies. Cancer. 1995; 75:2345–50.
15. Hosni A, Bezjak A, Rink A, Czarnecka K, McPartlin A, Patterson S, et al. High Dose Rate Brachytherapy as a Treatment Option in Endobronchial Tumors. Lung Cancer Int. 2016; 2016:3086148.
16. Rogus RD, Smith MJ, Kubo HD. An equation to QA check the total treatment time for single-catheter HDR brachytherapy. Int J Radiat Oncol Biol Phys. 1998; 40:245–8.
17. Wong T, Wallace S, Fernando W, Schumer W, Quong G. Dose errors in the near field of an HDR brachytherapy stepping source. Phys Med Biol. 1999; 44:357.
18. Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS. Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 1995; 22:209–34.
19. Fonseca GP, Viana RS, Podesta M, Rubo RA, Sales CP, Reniers B, et al. HDR 192Ir source speed measurements using a high speed video camera. Med Phys. 2015; 42:412–5.
20. Minamisawa R, Rubo R, Seraide R, Rocha J, Almeida A. Direct measurement of instantaneous source speed for a HDR brachytherapy unit using an optical fiber based detector. Med Phys. 2010; 37:5407–11.